Addex Therapeutics (ADXN) Net Cash Flow (2019 - 2025)

Addex Therapeutics has disclosed Net Cash Flow across 7 years of filings, most recently posting $604.8 billion for Q2 2025.

• Net Cash Flow for Q2 2025 came in at $604.8 billion, down 73.05% year-over-year; the trailing twelve-month figure through Dec 2025 was $47.9 billion (up 100.87% YoY), and the FY2025 annual result was -$2.0 million, down 182.69% from the prior year.
• Net Cash Flow came in at $604.8 billion for Q2 2025 at Addex Therapeutics, up from -$556.9 billion in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $2313.4 billion in Q4 2023 to a low of -$6057.2 billion in Q3 2024.
• The 5-year median for Net Cash Flow is -$2.2 million (2021), against an average of -$302.5 billion.
• Peak annual rise in Net Cash Flow reached 68771161.25% in 2023, while the deepest fall reached 178495159.36% in 2023.
• Addex Therapeutics' Net Cash Flow stood at $5.6 million in 2021, then tumbled by 159.79% to -$3.4 million in 2022, then jumped by 68771161.25% to $2313.4 billion in 2023, then slumped by 71.33% to $663.2 billion in 2024, then declined by 8.8% to $604.8 billion in 2025.
• The last three Net Cash Flow figures came in at $604.8 billion (Q2 2025), -$556.9 billion (Q1 2025), and $663.2 billion (Q4 2024), per Business Quant data.